Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Other Mar 30 | 2023Akero to Initiate Ph3 NASH Program; Bigfoot Acquires Insulin Titration Algorithm; GSK Collaborates with PathAI in NASHPurchase Blast
$599
Posted in: GLP-1RA, Other Mar 29 | 2023FDA Releases Framework for Use of Digital Health Technology in Clinical Trials; New Ph2 Dapiglutide Obesity TrialPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Mar 28 | 2023Viking Announces Positive Ph1 GLP-1/GIP Dual Agonist Topline Results and Initiates Oral Formulation Development; Zealand Ph1a Amylin Analog Results; Biomea Ph2 Menin Inhibitor ResultsPurchase Blast
$599
Posted in: Dual/triple agonist, Other Mar 27 | 2023Mounjaro Obesity Indication Filed in EU; March CHMP Agenda; Vertex Announces T1DM Licensing Agreement with CRISPR; Sanofi Helps Dario Secure Top-Ten PBM ContractPurchase Blast
$599
Posted in: GLP-1RA Mar 24 | 2023Positive High-Dose Oral Semaglutide Topline ResultsPurchase Blast
$599
Posted in: Other Mar 22 | 202389bio Positive Ph2b Pegozafermin NASH Data; Novartis Discontinues Inclisiran UK Primary Prevention Trial; Novo Nordisk Partners with Dewpoint Therapeutics; Evkeeza Receives Pediatric ApprovalPurchase Blast
$599
Posted in: GLP-1RA Mar 21 | 2023Altimmune Ph2 Obesity and Ph1b T2DM Pemvidutide DataPurchase Blast
$599
Posted in: Glucose Monitoring, Other Mar 21 | 2023Senseonics Q4 ’22 Earnings and CGM Investor Event; OrsoBio Doses First Patient in Ph2 TLC-3595 Trial for Insulin ResistancePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin Mar 17 | 2023Sanofi Follows Lilly and Novo's Insulin Price CutsPurchase Blast
$599
Posted in: Glucose Monitoring, Other Mar 15 | 2023Nemaura Includes Insulin in EU DuoPack License Agreement; Sigilon Q4 ‘22 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin Mar 14 | 2023Novo Nordisk to Lower US Insulin PricesPurchase Blast$599
Posted in: Other Mar 13 | 2023Sanofi Acquires Provention Bio; Ozempic Takes Stage at OscarsPurchase Blast
$599
Posted in: Dual/triple agonist, Other Mar 10 | 2023Mounjaro TV DTC Analysis; Intercept OCA Adcom SetPurchase Blast
$599
Posted in: Other Mar 09 | 2023Vertex Announces FDA Clearance of IND for VX-264 in T1DM; Akebia and Dario Q4 ’22 EarningsPurchase Blast
$599
Posted in: Glucagon, Other, SGLT2i Mar 08 | 2023FDA Accepts Jardiance Pediatric sNDA; New Teplizumab Pediatric Trial; Sernova Completes Islet Transplantation in First Two Ph1/2 T1DM Patients; Xeris and vTv Therapeutics Q4 ’22 EarningsPurchase Blast
$599
Posted in: Glucose Monitoring, Other, SGLT2i Mar 06 | 2023CLEAR Outcomes Full Results; Abbott Libre 2 and 3 AID Clearance; New Lexicon HF Awareness Campaign; Merck to Advance Oral PCSK9i to Ph3; Amarin Announces Non-Sarissa Board Departures; BI/Lilly COORDINATE-Diabetes ResultsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucagon, Glucose Monitoring, Other Mar 02 | 2023CMS Expands CGM Coverage; New Novo R&D Presence in Boston; Bigfoot Unity Android App Approval; Cytokinetic Receives Omecamtiv CRL; Galectin Finalizes Ph2b/3 NAVIGATE Randomization; Imcyse Completes Trial Enrollment; and Zealand, Intercept, and Amarin Q4 ’22 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin Mar 02 | 2023US Insulin Pricing Analysis: Lilly cuts insulin prices by 70% and caps out-of-pocket costs at $35 per monthPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other Feb 27 | 2023Esperion Launches Website Featuring CLEAR Outcomes; Abbott Receives 510(k) Approval for APIs; Novartis Initiates Ph3 Inclisiran Primary Prevention Trial; Nemaura and Viatris Q4 ’22 Earnings UpdatesPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
